Business Wire

Qvest to Accelerate Generative AI for Media and Entertainment Businesses in Collaboration with NVIDIA

10.9.2024 16:03:00 EEST | Business Wire | Press release

Share

IBC2024 -- Qvest, a leading consultant and systems integrator in media-focused services, today announced a collaboration with NVIDIA to drive AI adoption in the media and entertainment industry. These solutions powered by generative AI (GenAI), will create new opportunities for revenue generation, customer engagement, and operational efficiency.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910864873/en/

Christophe Ponsart - EVP and Applied AI Practice Co-Lead, Qvest US. (Photo: Business Wire)

Qvest is expanding its alliance program in artificial intelligence to further position the company as a leader in AI for media businesses. By fostering collaboration across industries and leveraging shared expertise, Qvest delivers tangible GenAI applications that drive ROI.

The collaboration with NVIDIA combines Qvest’s deep expertise in media and entertainment with NVIDIA’s leading AI capabilities and technology platform. This will deliver advanced AI-driven solutions that empower companies to harness the full potential of GenAI.

Using NVIDIA's AI technologies, Qvest is further developing GenAI offerings in its Applied AI practice that address the key business challenges of media companies and help increase their productivity, promote creativity and optimize processes.

“The collaboration with NVIDIA enables us to quickly deliver powerful use cases for media and entertainment companies. Together, we are helping our customers generate value from AI in areas most impactful for their business,” said Christophe Ponsart, EVP and Applied AI Practice Co-Lead, Qvest US.

A GenAI solution will be unveiled at the IBC Show in Amsterdam, streamlining content management and creation within existing media workflows for:

  • Automated Metadata Tagging: Drastically reduces time and costs associated with manual cataloging by automating structured metadata tagging across multiple modalities (text, audio, vision).
  • Accelerated Content Discovery: User enablement to quickly find relevant content across and within video assets.
  • Empowered Content Generation: Generation and iteration on contextually relevant headlines, scripts, and narratives in seconds to accelerate time to market.

“Media and entertainment companies are looking to accelerate AI adoption to deliver enhanced experiences. By combining NVIDIA’s AI platform with Qvest’s industry expertise, Qvest is empowering customers to quickly move from idea to scalable implementation using the latest developments in AI,” said Richard Kerris, Vice President of Media and Entertainment at NVIDIA.

NVIDIA NIM inference microservices play a critical role in this collaboration, offering seamless hosting of state-of-the-art GenAI models for computer vision, content generation, audio transcription, and more. Companies can choose where to run their models, whether in the cloud or hosted locally, helping ensure that data remains secure while optimizing performance.

Qvest is committed to continuing its collaboration with NVIDIA, with plans to integrate NVIDIAHoloscan for Media, an AI-enabled, software-defined platform for live media, for real-time streaming ingestion and content discovery. This integration will help further enhance the capabilities of GenAI infrastructure, increasing security, reducing costs, boosting performance, and minimizing operational overhead.

Qvest’s GenAI accelerators, developed in collaboration with NVIDIA, will be showcased at IBC 2024, where attendees can experience a full range of tangible and practical GenAI use cases firsthand at Qvest’s booth (#10.C24). More about Qvest at IBC2024 at www.qvest.com/ibc2024

About Qvest

Qvest is a global leader in media-focused practices and services. Qvest supports companies holistically in their Digital Transformation with innovation, consulting and technology implementation services to achieve future-oriented change. With deep expertise in media, information and communications technology, Qvest supports its customers in transforming their business towards digitalization, cloud and AI. Qvest's customers include numerous global brands from industries such as media & entertainment, telecommunications, automotive, health & pharmaceuticals, consumer goods, retail, transportation, and logistics, as well as organizations from the public sector. In addition to its headquarters in Germany, the company operates locations across Europe, the USA, the Middle East, Southeast Asia, and Australia.

www.qvest.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240910864873/en/

Contacts

Qvest Group GmbH
Christian Felder
Tel.: +49 174 9481 983
E-Mail: christian.felder@qvest.com
Web: www.qvest.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.qvest.com&e
sheet=54119793&newsitemid=20240910864873&lan=en-US&anchor=www.qvest.com&index=3&
md5=c0a5bdcc8dfc89ea26ad0ef9f0362b7d

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye